ANI PHARMACEUTICALS, INC Equity Securities, FV-NI, Unrealized Gain (Loss)
ANI PHARMACEUTICALS, INC (ANIP) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $741.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-08-07
- ANI PHARMACEUTICALS, INC equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was $741.00K, a 123.19% increase year-over-year.
- ANI PHARMACEUTICALS, INC equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was $5.75M.
- ANI PHARMACEUTICALS, INC equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was $273.00K.
- ANI PHARMACEUTICALS, INC equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was $3.14M, a 131.73% increase year-over-year.
- ANI PHARMACEUTICALS, INC equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was $2.82M, a 55.22% decline from fiscal 2024.
- ANI PHARMACEUTICALS, INC equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was $6.31M.
- ANI PHARMACEUTICALS, INC equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was $0.00.
- ANI PHARMACEUTICALS, INC equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was $0.00.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $741.00K 10-Q · filed 2026-08-07 | $6.49M 10-Q · filed 2026-08-07 | $6.77M derived: sum of 3 quarters · filed 2026-08-07 | $9.91M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $5.75M 10-Q · filed 2026-05-08 | $6.03M derived: sum of 2 quarters · filed 2026-05-08 | $9.17M derived: sum of 3 quarters · filed 2026-05-08 | $9.50M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $273.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $3.41M derived: sum of 2 quarters · filed 2026-02-27 | $3.75M derived: sum of 3 quarters · filed 2026-08-07 | $2.82M 10-K · filed 2026-02-27 |
| 2025-09-30 | $3.14M 10-Q · filed 2025-11-07 | $3.47M derived: sum of 2 quarters · filed 2026-08-07 | $2.55M 10-Q · filed 2025-11-07 | $560.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $332.00K 10-Q · filed 2026-08-07 | -$589.00K 10-Q · filed 2026-08-07 | -$2.58M derived: sum of 3 quarters · filed 2026-08-07 | -$1.23M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$921.00K 10-Q · filed 2026-05-08 | -$2.91M derived: sum of 2 quarters · filed 2026-05-08 | -$1.56M derived: sum of 3 quarters · filed 2026-05-08 | -$4.27M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$636.00K derived: sum of 2 quarters · filed 2026-02-27 | -$3.35M derived: sum of 3 quarters · filed 2026-02-27 | $6.31M 10-K · filed 2026-02-27 |
| 2024-09-30 | $1.35M 10-Q · filed 2025-11-07 | -$1.36M derived: sum of 2 quarters · filed 2025-11-07 | $8.30M 10-Q · filed 2025-11-07 | $8.30M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | -$2.71M 10-Q · filed 2025-08-08 | $6.94M 10-Q · filed 2025-08-08 | $6.94M derived: sum of 3 quarters · filed 2026-02-27 | $6.94M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $9.65M 10-Q · filed 2025-05-09 | $9.65M derived: sum of 2 quarters · filed 2026-02-27 | $9.65M derived: sum of 3 quarters · filed 2026-02-27 | $9.65M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-08 | $0.00 derived: sum of 2 quarters · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |